Philip B Gorelick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2960681/publications.pdf

Version: 2024-02-01

113 papers

8,774 citations

35 h-index 91 g-index

126 all docs

 $\begin{array}{c} 126 \\ \\ \text{docs citations} \end{array}$

times ranked

126

10388 citing authors

#	Article	IF	CITATIONS
1	Bilateral Non-Arteritic Anterior Ischaemic Optic Neuropathy in a Patient with a COL4A2 Mutation. Neuro-Ophthalmology, 2022, 46, 1-4.	1.0	O
2	Older women, blood pressure, and cognition. The Lancet Healthy Longevity, 2022, 3, e4-e5.	4.6	0
3	Community Engagement: Lessons Learned From the AAASPS and SDBA. Stroke, 2022, 53, 654-662.	2.0	3
4	Oneâ€Year Blood Pressure Trajectory After Acute Ischemic Stroke. Journal of the American Heart Association, 2022, 11, e023747.	3.7	2
5	Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis and Rheumatology, 2022, 74, 1593-1601.	5 . 6	10
6	Effect of Heart Rate on 1â€Year Outcome for Patients With Acute Ischemic Stroke. Journal of the American Heart Association, 2022, 11, e025861.	3.7	6
7	Vascular health across young adulthood and midlife cerebral autoregulation, gait, and cognition. Alzheimer's and Dementia, 2021, 17, 745-754.	0.8	4
8	Five‥ear Risk of Acute Myocardial Infarction After Acute Ischemic Stroke in Korea. Journal of the American Heart Association, 2021, 10, e018807.	3.7	11
9	Treatment Intensification for Elevated Blood Pressure and Risk of Recurrent Stroke. Journal of the American Heart Association, 2021, 10, e019457.	3.7	4
10	Vascular health and diffusion properties of normal appearing white matter in midlife. Brain Communications, 2021, 3, fcab080.	3.3	7
11	Career Development Program for Underrepresented in Medicine Scholars in Academic Neurology. Neurology, 2021, 97, 125-133.	1.1	7
12	Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Circulation, 2021, 143, 2441-2453.	1.6	21
13	Aspirin Use and Risk of Subdural Hematoma: Updated Meta-Analysis of Randomized Trials. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105911.	1.6	2
14	Hypertension and cognitive dysfunction: a review of mechanisms, life-course observational studies and clinical trial results. Reviews in Cardiovascular Medicine, 2021, 22, 1429.	1.4	15
15	Are large simple trials for dementia prevention possible?. Age and Ageing, 2020, 49, 154-160.	1.6	17
16	Effect of Heart Rate on Stroke Recurrence and Mortality in Acute Ischemic Stroke With Atrial Fibrillation. Stroke, 2020, 51, 162-169.	2.0	36
17	Cognitive function in SPRINT: where do we go next?. Lancet Neurology, The, 2020, 19, 880-881.	10.2	8
18	Natural History of Hemodynamics in Vertebrobasilar Disease. Stroke, 2020, 51, 3295-3301.	2.0	11

#	Article	IF	CITATIONS
19	Blood Pressure Management in Stroke. Hypertension, 2020, 76, 1688-1695.	2.7	17
20	Tackling challenges in care of Alzheimer's disease and other dementias amid the COVIDâ€19 pandemic, now and in the future. Alzheimer's and Dementia, 2020, 16, 1571-1581.	0.8	122
21	The interplay between COVID 19 and non-communicable diseases. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105104.	1.6	1
22	Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack. Neurology, 2020, 95, e2178-e2191.	1.1	44
23	Three-month modified Rankin Scale as a determinant of 5-year cumulative costs after ischemic stroke. Neurology, 2020, 94, e978-e991.	1.1	26
24	Relationship between blood pressure and outcome changes over time in acute ischemic stroke. Neurology, 2020, 95, e1362-e1371.	1.1	7
25	Statin therapy in acute cardioembolic stroke with no guidance-based indication. Neurology, 2020, 94, e1984-e1995.	1.1	21
26	Routing to Endovascular Treatment of Ischemic Stroke in Korea: Recognition of Need for Process Improvement. Journal of Korean Medical Science, 2020, 35, e347.	2.5	9
27	Perspectives on the relation of blood pressure and cognition in the elderly. Trends in Cardiovascular Medicine, 2019, 29, 12-18.	4.9	6
28	Brain White Matter: A Substrate for Resilience and a Substance for Subcortical Small Vessel Disease. Brain Sciences, 2019, 9, 193.	2.3	12
29	Stroke knowledge among middle and high school students. Journal of International Medical Research, 2019, 47, 4230-4241.	1.0	14
30	Management of blood pressure in stroke. International Journal of Cardiology: Hypertension, 2019, 3, 100021.	2.2	8
31	An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial. Lancet, The, 2019, 394, 219-229.	13.7	41
32	Sphenopalatine Ganglion Stimulation to Augment Cerebral Blood Flow. Stroke, 2019, 50, 2108-2117.	2.0	24
33	The global burden of stroke: persistent and disabling. Lancet Neurology, The, 2019, 18, 417-418.	10.2	412
34	Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. Stroke, 2019, 50, 1184-1192.	2.0	16
35	Quality of acute stroke care in Korea (2008–2014): Retrospective analysis of the nationwide and nonselective data for quality of acute stroke care. European Stroke Journal, 2019, 4, 337-346.	5.5	11
36	Hypoperfusion Symptoms Poorly Predict Hemodynamic Compromise and Stroke Risk in Vertebrobasilar Disease. Stroke, 2019, 50, 495-497.	2.0	14

3

#	Article	IF	CITATIONS
37	In-Hospital and Post-Discharge Recovery after Acute Ischemic Stroke: a Nationwide Multicenter Stroke Registry-base Study. Journal of Korean Medical Science, 2019, 34, e240.	2.5	12
38	Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine, 2018, 378, 1200-1210.	27.0	601
39	Discrete Time Survival Analysis Via Latent Variable Modeling: A Note on Lagged Depression Links to Stroke in Middle and Late Life. Structural Equation Modeling, 2018, 25, 115-120.	3.8	3
40	Prevention of cognitive impairment: scientific guidance and windows of opportunity. Journal of Neurochemistry, 2018, 144, 609-616.	3.9	25
41	Predictive Value of Pulse Pressure in Acute Ischemic Stroke for Future Major Vascular Events. Stroke, 2018, 49, 46-53.	2.0	196
42	Vascular risk burden, brain health, and next steps. Neurology, 2018, 91, 729-730.	1.1	7
43	Trajectory Groups of 24-Hour Systolic Blood Pressure After Acute Ischemic Stroke and Recurrent Vascular Events. Stroke, 2018, 49, 1836-1842.	2.0	31
44	Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 392, 1036-1046.	13.7	619
45	On the Potential of Discrete Time Survival Analysis Using Latent Variable Modeling: An Application to the Study of the Vascular Depression Hypothesis. Structural Equation Modeling, 2017, 24, 926-935.	3.8	10
46	Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association. Stroke, 2017, 48, e284-e303.	2.0	279
47	An exploratory study of the electronic medical record and outpatient vascular neurology consultations. Neurological Sciences, 2017, 38, 2195-2198.	1.9	0
48	Higher Stroke Risk with Lower Blood Pressure in Hemodynamic Vertebrobasilar Disease: Analysis from the VERiTAS Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 403-410.	1.6	30
49	Impact of Guidelines on Clinical Practice. Stroke, 2016, 47, 1577-1583.	2.0	5
50	Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension, 2016, 68, e67-e94.	2.7	482
51	Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. Annals of Neurology, 2016, 79, 560-568.	5.3	35
52	Pathophysiology and management of reperfusion injury and hyperperfusion syndrome after carotid endarterectomy and carotid artery stenting. Experimental & Translational Stroke Medicine, 2016, 8, 7.	3.2	90
53	Cerebral Microbleeds, Cognition, and Therapeutic Implications. JAMA Neurology, 2016, 73, 908.	9.0	6
54	Neurology Case Studies. Neurologic Clinics, 2016, 34, 467-482.	1.8	1

#	Article	IF	CITATIONS
55	Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?. International Journal of Stroke, 2016, 11, 783-790.	5.9	10
56	Ambulatory Blood Pressure and Stroke. , 2016, , 193-206.		1
57	Vascular cognitive impairment and dementia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 860-868.	3.8	130
58	Progressive central nervous system vasculopathy in sarcoidosis: A case report. Journal of the Neurological Sciences, 2016, 362, 153-154.	0.6	6
59	Adaptation of neurological practice and policy to a changing US health-care landscape. Lancet Neurology, The, 2016, 15, 444-450.	10.2	5
60	Effect of Hemodynamics on Stroke Risk in Symptomatic Atherosclerotic Vertebrobasilar Occlusive Disease. JAMA Neurology, 2016, 73, 178.	9.0	126
61	A Case of Complex PFO Leading to Ischemic Stroke. Neurohospitalist, The, 2016, 6, 114-117.	0.8	0
62	Blood pressure variability and the development of early neurological deterioration following acute ischemic stroke. Journal of Hypertension, 2015, 33, 2099-2106.	0.5	70
63	Alpha-Linolenic Acid: An Omega-3 Fatty Acid with Neuroprotective Properties—Ready for Use in the Stroke Clinic?. BioMed Research International, 2015, 2015, 1-8.	1.9	116
64	HRS/NSA 2014 survey of atrial fibrillation and stroke: Gaps in knowledge and perspective, opportunities for improvement. Heart Rhythm, 2015, 12, e105-e113.	0.7	26
65	Hemodynamic Features of Symptomatic Vertebrobasilar Disease. Stroke, 2015, 46, 1850-1856.	2.0	45
66	Stroke and Cognitive Decline. JAMA - Journal of the American Medical Association, 2015, 314, 29.	7.4	29
67	Comparative Effectiveness of Standard Care With IV Thrombolysis Versus Without IV Thrombolysis for Mild Ischemic Stroke. Journal of the American Heart Association, 2015, 4, e001306.	3.7	24
68	World Stroke Day Proclamation 2015. Stroke, 2015, 46, 3037-3038.	2.0	9
69	HRS/NSA 2014 Survey of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1691-1700.	1.6	27
70	Moderate alcohol intake reduces risk of ischemic stroke in Korea. Neurology, 2015, 85, 1950-1956.	1.1	23
71	Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours. Stroke, 2015, 46, 2541-2548.	2.0	56
72	Should blood pressure be lowered in acute ischemic stroke? The CATIS trial. Journal of the American Society of Hypertension, 2015, 9, 331-333.	2.3	2

#	Article	IF	CITATIONS
73	Stroke: an emphasis on guidelines. Lancet Neurology, The, 2015, 14, 2-3.	10.2	10
74	Reviving Intracranial Angioplasty and Stenting \tilde{A} ¢â,¬Å"SAMMPRIS and beyond \tilde{A} ¢â,¬Â• Frontiers in Neurology, 2014, 5, 101.	2.4	10
75	Gender Differences in the Age-Stratified Prevalence of Risk Factors in Korean Ischemic Stroke Patients: A Nationwide Stroke Registry-Based Cross-Sectional Study. International Journal of Stroke, 2014, 9, 759-765.	5.9	37
76	Restricted Diffusion of the Splenium of the Corpus Callosum in Viral Meningitis. Neurohospitalist, The, 2014, 4, 109-110.	0.8	5
77	Blood Pressure and the Prevention of Cognitive Impairment. JAMA Neurology, 2014, 71, 1211.	9.0	25
78	New Guidelines to Reduce Risk of Atherosclerotic Cardiovascular Disease. Stroke, 2014, 45, 945-947.	2.0	12
79	The Management of Hypertension for an Acute Stroke: What Is the Blood Pressure Goal?. Current Cardiology Reports, 2013, 15, 366.	2.9	14
80	Advances in Vascular Cognitive Impairment. Stroke, 2013, 44, 307-308.	2.0	23
81	A New Era of Neurologic Practice, the Need to Shift the Residency Training Paradigm, and the Importance of Hospitalist Neurology. Neurohospitalist, The, 2013, 3, 117-119.	0.8	4
82	Advances in Our Understanding of "Resistance―to Antiplatelet Agents for Prevention of Ischemic Stroke. Stroke Research and Treatment, 2013, 2013, 1-7.	0.8	11
83	Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack. Circulation, 2013, 128, 1656-1666.	1.6	118
84	Effect of blood pressure on 3-month functional outcome in the subacute stage of ischemic stroke. Neurology, 2012, 79, 2018-2024.	1.1	66
85	Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. Journal of the American Society of Hypertension, 2012, 6, 309-315.	2.3	55
86	Reducing blood pressure variability to prevent stroke?. Lancet Neurology, The, 2010, 9, 448-449.	10.2	15
87	Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke Study (Veritas): Rationale and Design. International Journal of Stroke, 2010, 5, 499-505.	5.9	39
88	Effect of Sex on Outcome after Recurrent Stroke in African Americans: Results from the African American Antiplatelet Stroke Prevention Study. Journal of Stroke and Cerebrovascular Diseases, 2010, 19, 321-325.	1.6	2
89	Advances in Vascular Cognitive Impairment. Stroke, 2010, 41, e93-8.	2.0	22
90	Management of Blood Pressure for Acute and Recurrent Stroke. Stroke, 2009, 40, 2251-2256.	2.0	90

#	Article	IF	CITATIONS
91	Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1647-1652.	2.0	450
92	Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine, 2008, 359, 1238-1251.	27.0	882
93	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	2.0	1,510
94	Impact of Obesity and the Metabolic Syndrome on Risk Factors in African American Stroke Survivors. Archives of Neurology, 2005, 62, 386.	4.5	30
95	William M. Feinberg Lecture: Cognitive Vitality and the Role of Stroke and Cardiovascular Disease Risk Factors. Stroke, 2005, 36, 875-879.	2.0	60
96	Prevention of Stroke Recurrence. International Psychogeriatrics, 2003, 15, 167-171.	1.0	3
97	Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2003, 289, 2947.	7.4	225
98	North American perspective of antiplatelet agents. Advances in Neurology, 2003, 92, 281-91.	0.8	2
99	Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy. Stroke, 2002, 33, 862-875.	2.0	205
100	Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia. Neurology, 2002, 58, 56-61.	1.1	45
101	Predictors of survival in African American patients with AD, VaD, or stroke without dementia. Neurology, 2002, 59, 1146-1153.	1.1	40
102	Stroke Risk Factor Profiles in African American Women. Stroke, 2002, 33, 913-919.	2.0	27
103	New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurology, The, 2002, 1, 149-156.	10.2	70
104	Autopsy Recruitment Program for African Americans. Alzheimer Disease and Associated Disorders, 2000, 14, 202-208.	1.3	44
105	Should we be screening relatives of patients with aneurysmal subarachnoid hemorrhage for asymptomatic intracranial aneurysm?. Current Atherosclerosis Reports, 2000, 2, 89-91.	4.8	3
106	Prevention of Vascular Dementia. Alzheimer Disease and Associated Disorders, 1999, 13, S131-139.	1.3	27
107	African American caregivers' preferences for life-sustaining treatment. Journal of Ethics, Law, and Aging, 1999, 5, 3-15.	0.0	7
108	African American antiplatelet stroke prevention study: Clinical trial design. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 426-434.	1.6	28

PHILIP B GORELICK

#	Article	IF	CITATIONS
109	Cerebrovascular Disease in African Americans. Stroke, 1998, 29, 2656-2664.	2.0	127
110	Status of Risk Factors for Dementia Associated With Stroke. Stroke, 1997, 28, 459-463.	2.0	102
111	Stroke in Elderly African-Americans. The American Journal of Geriatric Cardiology, 1997, 6, 39-49.	0.6	8
112	Risk Factors for Dementia Associated With Multiple Cerebral Infarcts. Archives of Neurology, 1993, 50, 714.	4.5	107
113	Quantitative Measurement of Delta Activity in Alzheimer's Disease. Clinical EEG (electroencephalography), 1991, 22, 178-182.	0.9	30